Asset profile
SHR6508
Small molecule
Evidence outlook · lead readout
NCT06236295 · Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT06236295: The study is a single-group, unblinded trial of 303 participants, with no placebo or active comparator. Its primary endpoint is the incidence and severity of adverse events, but results are not posted, so whether this endpoint was met cannot be determined.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.